-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QmDDs/R0G1y/aDsgfayol5zG62BtQT1/2KPpXGA/u4czSzu6fgfAmwBMFoDEAOZg qxoKKF1tIqVRAg/cHvTBDw== 0000950133-01-500418.txt : 20010410 0000950133-01-500418.hdr.sgml : 20010410 ACCESSION NUMBER: 0000950133-01-500418 CONFORMED SUBMISSION TYPE: POS AM PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20010404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVAVAX INC CENTRAL INDEX KEY: 0001000694 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222816046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: POS AM SEC ACT: SEC FILE NUMBER: 333-05367 FILM NUMBER: 1595165 BUSINESS ADDRESS: STREET 1: 8320 GUILFORD RD STREET 2: STE C CITY: COLUMBIA STATE: MD ZIP: 21046 BUSINESS PHONE: 3078543900 MAIL ADDRESS: STREET 1: 8320 GUILFORD ROAD SUITE C STREET 2: 12111 PARKLAWN DR CITY: COLUMBIA STATE: MD ZIP: 21046 POS AM 1 w47451aposam.txt POST-EFFECTIVE AMENDMENT, FORM S-3 1 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 6, 1996 REGISTRATION NO. 333-05367 ================================================================================ SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NOVAVAX, INC. (Exact name of registrant as specified in its charter) DELAWARE 22-2816046 (State of incorporation) (I.R.S. Employer Identification Number) 8320 GUILFORD ROAD COLUMBIA, MD 21046 (301) 854-3900 (Address, including zip code, and telephone number, of registrant's principal executive offices) JOHN A. SPEARS PRESIDENT AND CHIEF EXECUTIVE OFFICER NOVAVAX, INC. 8320 GUILFORD ROAD COLUMBIA, MD 21046 (301) 854-3900 (Name, address, including zip code, and telephone number, of agent for service of process) With a copy to: -------------- DAVID A. WHITE, ESQ. WHITE & MCDERMOTT, P.C. 65 WILLIAM STREET WELLESLEY, MASSACHUSETTS 02481 (781) 431-1700 Approximate date of commencement of proposed sale to the public: As soon as practicable and from time to time after the effective date of this Registration Statement. If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. [ ] 2 If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. [ ] If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ] If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [X] If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. [ ] PURPOSE OF AMENDMENT The contents of the Novavax, Inc. (the "Registrant") Registration Statement on Form S-3, No. 333-05367, as filed with the Securities and Exchange Commission ("SEC") on June 6, 1996 (the "June 1996 Registration Statement") are hereby incorporated herein by reference to the extent not replaced hereby. The Registrant registered 240,411 shares of its common stock in the June 1996 Registration Statement, 55,749 shares of which have not been sold or otherwise transferred. Pursuant to an undertaking in Item 17(a)(3) of the June 1996 Registration Statement, the Registrant hereby requests deregistration of the 55,749 shares of the Registrant's common stock previously registered under the June 1996 Registration Statement which have not been sold or otherwise transferred. 3 SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Columbia, State of Maryland on March 28, 2001. NOVAVAX, INC. By: /s/ Dennis Genge ----------------------------------- Dennis Genge, Vice President and Treasurer, Chief Financial Officer
NAME TITLE DATE ---- ----- ---- /s/ John A. Spears President and March 28, 2001 - ------------------ Chief Executive Officer John A. Spears and Director /s/ Dennis W. Genge Vice President and Treasurer March 28, 2001 - ------------------- Chief Financial Officer Dennis W. Genge (Principal Financial and Accounting Officer) Director March 28, 2001 - ----------------- Gary C. Evans /s/ William E. Georges Director March 28, 2001 - ---------------------- William E. Georges /s/ Mitchell J. Kelly Director March 28, 2000 - --------------------- Mitchell J. Kelly
4 /s/ J. Michael Lazarus Director March 28, 2001 - ---------------------- J. Michael Lazarus /s/ John O. Marsh, Jr. Director March 28, 2001 - ---------------------- John O. Marsh, Jr. /s/ Michael A. McManus Director March 28, 2001 - ---------------------- Michael A. McManus Director March 28, 2001 - ---------------------- Denis M. O'Donnell /s/ Ronald H. Walker Director March 28, 2001 - -------------------- Ronald H. Walker
-----END PRIVACY-ENHANCED MESSAGE-----